Charles Schwab Investment Management Inc Prelude Therapeutics Inc Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 117,200 shares of PRLD stock, worth $118,372. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,200

Previous 133,249 12.04%

Holding current value

$118,372

Previous $275,000 46.18%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	SELL	$0.8 - $2.04 $12,839 - $32,739	-16,049 Reduced 12.04%	117,200 $148,000
Q3 2024 Nov 12, 2024	BUY	$2.07 - $6.37 $10,797 - $33,225	5,216 Added 4.07%	133,249 $275,000
Q2 2024 Aug 12, 2024	BUY	$3.32 - $5.63 $2,201 - $3,732	663 Added 0.52%	128,033 $487,000
Q1 2024 May 08, 2024	BUY	$2.68 - $4.84 $7,155 - $12,922	2,670 Added 2.14%	127,370 $603,000
Q4 2023 Feb 06, 2024	BUY	$1.69 - $4.37 $2,820 - $7,293	1,669 Added 1.36%	124,700 $532,000
Q3 2023 Nov 08, 2023	BUY	$2.74 - $4.79 $102,032 - $178,370	37,238 Added 43.4%	123,031 $380,000
Q2 2023 Aug 09, 2023	BUY	$4.45 - $8.12 $102,091 - $186,289	22,942 Added 36.5%	85,793 $386,000
Q1 2023 May 11, 2023	SELL	$4.58 - $7.34 $3,984 - $6,385	-870 Reduced 1.37%	62,851 $358,000
Q4 2022 Feb 13, 2023	BUY	$4.61 - $8.5 $44,574 - $82,186	9,669 Added 17.89%	63,721 $384,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $45,740 - $80,685	-9,148 Reduced 14.47%	54,052 $358,000
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $50,920 - $96,111	-12,730 Reduced 16.77%	63,200 $330,000
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $63,528 - $121,716	-9,207 Reduced 10.81%	75,930 $524,000
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $13,697 - $36,564	1,152 Added 1.37%	85,137 $1.06 Million
Q3 2021 Nov 16, 2021	BUY	$25.78 - $38.65 $292,912 - $439,141	11,362 Added 15.65%	83,985 $2.63 Million
Q2 2021 Aug 16, 2021	SELL	$28.63 - $44.3 $58,548 - $90,593	-2,045 Reduced 2.74%	72,623 $2.08 Million
Q1 2021 May 17, 2021	BUY	$39.27 - $91.68 $239,547 - $559,248	6,100 Added 8.9%	74,668 $3.24 Million
Q4 2020 Feb 16, 2021	BUY	$28.81 - $88.94 $1.98 Million - $6.1 Million	68,568 New	68,568 $4.91 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.9M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $36.7M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Prelude Therapeutics Inc Transaction History